Safety study of avalglucosidase alfa during pregnancy
Official title: A Descriptive Safety Study Based on Data Collected From Women and Their Offspring Exposed to Nexviazyme/Nexviadyme (Avalglucosidase Alfa-ngpt/Avalglucosidase Alfa) During Pregnancy and/or Lactation in the Postmarketing Setting
Run by Sanofi · NCT05734521 · Data updated 2026-11-12
This study is looking at how safe the drug avalglucosidase alfa is for pregnant women and their babies during pregnancy and breastfeeding.
Quick facts
| Study type | Observational |
|---|---|
| Sex | Women only |
| Enrollment | 100 (estimated) |
| Sponsor | Sanofi Industry-sponsored |
| Locations | 1 site (Bridgewater, New Jersey) |
| Status | Recruiting |
| Started | October 26, 2022 |
| Main results expected | October 31, 2032 |
| Study ends | October 31, 2032 |
| Registry record updated | January 16, 2026 |
| Trial ID | NCT05734521 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include women who have been exposed to avalglucosidase alfa during pregnancy or lactation and have consented to participate.
✕Probably not a fit
Patients who have not been exposed to avalglucosidase alfa during pregnancy or lactation may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to collect data on the safety of avalglucosidase alfa in women and their offspring during pregnancy and lactation. It will assess potential risks and complications associated with the drug for both mothers and their developing children. The study will follow participants for at least 10 years, evaluating outcomes in exposed infants, including their growth and development through the first year of life. Data will be gathered retrospectively and prospectively to provide a comprehensive understanding of the drug's effects.
Why it matters
Potential benefit: If successful, this study could provide critical safety information for pregnant women with Pompe disease using avalglucosidase alfa.
How similar studies have gone: While this study focuses on a specific population, similar observational studies have provided valuable safety data for other medications during pregnancy.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Women and their offspring exposed to avalglucosidase alfa during pregnancy and/or lactation for whom an Individual Case Safety Report (ICSR) has been submitted to the Sanofi Global Pharmacovigilance (PV) department, and/or, * Women exposed to avalglucosidase alfa during pregnancy and/or lactation who have provided informed consent to enroll in the Pompe Pregnancy Sub-registry. Exclusion Criteria: There are no exclusion criteria in this study. The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.
Where it's running
-
Investigational site worldwide
Bridgewater, New Jersey, United States Recruiting
Study contacts
- Study coordinator: Trial Transparency email recommended (Toll free for US & Canada)
- Email: Contact-US@sanofi.com
- Phone: 800-633-1610
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Pregnant Women Living with HIV on Bictegravir/Emtricitabine/Tenofovir Alafenamide
This study looks at how B/F/TAF is used in pregnant women with HIV and whether it helps maintain viral suppression from before conception through delivery.
-
Pelvic Floor Training and a Modified Lumbopelvic Belt for Symphysis Pubis Pain in Pregnancy
This study tests whether pelvic floor muscle training plus a modified lumbopelvic belt can reduce pain and improve function for pregnant women with symphysis pubis pain.
-
Effective Communication in VBAC Counseling
This study tests how clearly doctors and midwives explain VBAC options during prenatal visits and whether patients feel understood.
-
Innovative Multidisciplinary and Virtual Care for IBD in Pregnancy
This study tests a dedicated IBD pregnancy care model, including a new virtual approach, to see if it improves access and quality of care for pregnant people with Crohn's disease or ulcerative colitis.
-
Compare spinal-epidural versus general anesthesia for babies after cesarean delivery
This trial tests whether the type of anesthesia used for cesarean delivery affects newborn hearing in babies.
-
Pompe disease long-term monitoring with avalglucosidase alfa
This is an observational program to see how people with Pompe disease who started avalglucosidase alfa fare over time, including biomarkers, muscle and breathing function, and safety.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.